How Do Classical & Alternative C3/C5 Convertases Differ? Implications for Diagnostic Assay Design

The difference begins at the molecular core of the cascade: the C3 and C5 convertase complexes.
In the classical pathway, the surface-bound enzyme C4b2a serves as the C3 convertase, and upon capturing an additional C3b molecule it becomes the C5 convertase (C4b2a3b). The alternative pathway uses a fundamentally different assembly—its C3 convertase is C3bBb (stabilized by Properdin), and its C5 convertase is C3bBb3b. This compositional distinction is not just a biochemical nuance; it is the very foundation that allows diagnostic assays to isolate and measure each pathway independently.

The classical pathway builds its convertases from C4 and C2 (C4b2a, C4b2a3b), whereas the alternative pathway uses C3 and Factor B (C3bBb, C3bBb3b). This molecular difference enables pathway-specific functional testing by exploiting the classical pathway’s strict dependence on calcium ions and antibody‑sensitized surfaces—conditions the alternative pathway does not require.

The Convertase Difference: Classical vs. Alternative Pathway Assemblies

The Classical C3 Convertase: C4b2a

The classical pathway is triggered when the C1 complex (C1q, C1r, C1s) binds to antibody‑antigen clusters.
Active C1s then cleaves C4 into C4b, which covalently attaches to the target surface. C4b next binds C2 in a magnesium‑dependent manner, and C1s cleaves C2 to release C2b while retaining the catalytic C2a fragment. The resulting classical C3 convertase is C4b2a, where C4b anchors the complex and C2a provides the serine‑protease active site that clips C3 into C3a and C3b.

The Alternative C3 Convertase: C3bBb

The alternative pathway begins without antibody. It relies on the spontaneous tick‑over hydrolysis of C3 or direct deposition of C3b onto activating surfaces (e.g., microbial polysaccharides).
Surface‑bound C3b recruits Factor B, which is then cleaved by Factor D into Ba (released) and Bb (bound). The alternative C3 convertase is C3bBb, a short‑lived complex that is markedly stabilized by the oligomeric protein Properdin. Properdin binding extends the half‑life of C3bBb, amplifying the feedback loop of C3 cleavage.

Converting C3 to C5 Activity: The Key Step

Once a C3 convertase generates a high local density of C3b, the next level of amplification occurs.
A single additional C3b molecule binds adjacent to the C3 convertase and switches its substrate specificity from C3 to C5.

• Classical C5 convertase: C4b2a3b (the classical C3 convertase decorated with a neighboring C3b).
• Alternative C5 convertase: C3bBb3b (the alternative C3 convertase plus an extra C3b).

This substrate‑switching event is the critical checkpoint before terminal pathway activation and MAC formation. Partitioning the convertases into distinct molecular entities is what makes it possible to pinpoint whether a deficiency resides in the proximal classical components (C1, C4, C2) or in the alternative pathway factors (Factor B, Factor D, Properdin).

Implications for Diagnostic Assay Design

Pathway‑Specific Functional Assays (CH50 vs. AH50)

The classical complement activity test (CH50) and the alternative pathway assay (AH50) use fundamentally different triggers and ionic conditions that directly exploit the convertase compositions.

• CH50 (Classical Pathway): Uses antibody‑sensitized sheep red blood cells (EA complexes) as the activator. Because the classical C1 complex requires calcium ions for its C1q‑(C1r‑C1s)2 assembly, the assay buffer contains both Ca²⁺ and Mg²⁺. Lysis of the sensitized cells indicates a functional classical cascade.
• AH50 (Alternative Pathway): Uses unsensitized rabbit red blood cells, which naturally activate the alternative pathway without antibody. The assay buffer includes EGTA to chelate Ca²⁺, effectively shutting down the classical and lectin pathways, while leaving Mg²⁺ available (Mg‑EGTA) to support the alternative C3bBb convertase assembly.
  A low CH50 with a normal AH50 immediately points to a classical component deficiency; low results in both assays suggest a defect in the common terminal components (C3–C9).

Solid‑Phase ELISA Approaches

Commercial pathway‑specific ELISA kits exploit surface coatings and buffer chelation to isolate convertase activity.

• Classical Pathway ELISA: Wells are coated with IgM to capture C1q and initiate the CP cascade from diluted patient serum (e.g., 1:101).
• Lectin Pathway ELISA: Solid phase coated with mannose to bind mannan‑binding lectin, with anti‑C1q antibodies added to the buffer to block concurrent CP activation.
• Alternative Pathway ELISA: Wells coated with bacterial lipopolysaccharides (LPS) at lower serum dilutions (e.g., 1:18). The reaction buffer uses Mg‑EGTA to chelate calcium while preserving magnesium—exactly the same principle as the AH50 test—ensuring only C3bBb convertase assembly drives signal generation.

Raw Material Selection and Reagent Quality

The molecular precision of these assays depends on high‑purity, functionally active raw materials.
Manufacturers must source intact complement components (e.g., purified C4, C2, Factor B, Factor D, Properdin) and specific antibodies (anti‑C1q, anti‑C3a, anti‑C5a) that do not cross‑react or spontaneously activate in liquid formulations.
Diagnostic calibrators and control sera must be formulated to preserve pathway‑specific convertase formation; even trace amounts of cleaved C4 or Factor B can produce false‑positive signals. For IVD developers, the requirement is unambiguous: raw material integrity directly drives assay reliability.

Understanding the Trade‑offs and Pitfalls

Diagnostic assays built on convertase composition carry inherent challenges.

• Ion sensitivity: EGTA chelates Ca²⁺ but not Mg²⁺; however, prolonged exposure or incorrect pH can partially destabilize Mg²⁺‑dependent complexes, leading to underestimation of alternative pathway activity.
• Cross‑activation: In serum‑based ELISA, small amounts of spontaneous C3 hydrolysis or contact‑phase activation can generate background alternative pathway signal, even in CP‑specific buffers. Proper blocking and dilution are essential.
• Properdin instability: Properdin is labile and aggregates easily; if it precipitates out, the C3bBb complex decays rapidly. This can cause false‑low AH50 values or ELISA signals.
• Sample handling: Serum must be processed and frozen promptly. Repeated freeze‑thaw cycles activate C3 and deplete Factor B, compromising both convertase formation and differential power of the assay.
• Interpretation overlap: A defect in C3 (common to both pathways) will dampen both CH50 and AH50, but careful titration and adding purified components can resolve whether the problem lies in C3 itself or in a specific convertase.

Making the Right Choice for Your Diagnostic Goal

The choice of assay format and buffer system should be driven by the specific clinical or research question you need to answer.

• If your primary focus is differentiating a classical pathway defect: Use a CH50 assay with antibody‑sensitized SRBCs or an IgM‑coated ELISA under Ca²⁺/Mg²⁺‑containing conditions. A decreased result, paired with a normal AH50, isolates C1, C4, or C2 deficiencies.
• If your primary focus is detecting alternative pathway abnormalities: Rely on the AH50 assay with unsensitized rabbit RBCs and Mg‑EGTA buffer, or an LPS‑coated ELISA with the same chelator strategy. This setup exclusively reflects the activity of the C3bBb convertase and its stabilizing factor Properdin.
• If your primary focus is identifying common terminal pathway or C3 deficiencies: Run both CH50 and AH50 in parallel. Diminished lysis or signal in both tests strongly indicates a defect at or after the point of convergence—the C3 convertase step—encompassing C3 itself or terminal components (C5–C9).
• If your primary focus is developing a robust IVD kit: Prioritize sourcing intact, functionally validated complement proteins and antibodies, and bake in rigorous buffer‑ion controls (Ca²⁺, Mg²⁺, EGTA) to guarantee that only the intended convertase will form in your reaction well.

The convertase composition of the classical and alternative pathways is more than an academic detail—it is the precision tool that allows you to surgically dissect complement function and deliver a clear diagnostic picture.

Summary Table:

Developing precise pathway-specific complement assays requires uncompromising reagent quality and specialized expertise. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-purity IVD raw materials, technical services, and consulting—covering every stage of assay development from concept to clinic.

Contact CamelBio today to elevate your diagnostic assay performance and streamline your raw material sourcing!